Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 2
2016 2
2017 2
2019 1
2020 1
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

7 results

Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
Identification of new SNPs associated with severe toxicity to capecitabine.
Pellicer M, García-González X, García MI, Robles L, Grávalos C, García-Alfonso P, Pachón V, Longo F, Martínez V, Blanco C, Iglesias I, Sanjurjo M, López-Fernández LA. Pellicer M, et al. Pharmacol Res. 2017 Jun;120:133-137. doi: 10.1016/j.phrs.2017.03.021. Epub 2017 Mar 27. Pharmacol Res. 2017. PMID: 28347776
Predicting individual risk of chemotherapy-induced severe adverse reaction is a critical issue when selecting the best treatment for cancer patients. ...These new variants could increase the predictive power of currently available tests and thus prevent …
Predicting individual risk of chemotherapy-induced severe adverse reaction is a critical issue when selecting the best …
Cost-Effectiveness of Pharmacogenomics-Guided Prescribing to Prevent Gene-Drug-Related Deaths: A Decision-Analytic Model.
van der Wouden CH, Marck H, Guchelaar HJ, Swen JJ, van den Hout WB. van der Wouden CH, et al. Front Pharmacol. 2022 Jun 28;13:918493. doi: 10.3389/fphar.2022.918493. eCollection 2022. Front Pharmacol. 2022. PMID: 36120299 Free PMC article.
Aim: Prospective studies support the clinical impact of pharmacogenomics (PGx)-guided prescribing to reduce severe and potentially fatal adverse effects. Drug-gene interactions (DGIs) preventing potential drug-related deaths have been categorized as "essentia …
Aim: Prospective studies support the clinical impact of pharmacogenomics (PGx)-guided prescribing to reduce severe and potentially fa …
Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction of DPYD and fluoropyrimidines.
Lunenburg CATC, van der Wouden CH, Nijenhuis M, Crommentuijn-van Rhenen MH, de Boer-Veger NJ, Buunk AM, Houwink EJF, Mulder H, Rongen GA, van Schaik RHN, van der Weide J, Wilffert B, Deneer VHM, Swen JJ, Guchelaar HJ. Lunenburg CATC, et al. Eur J Hum Genet. 2020 Apr;28(4):508-517. doi: 10.1038/s41431-019-0540-0. Epub 2019 Nov 19. Eur J Hum Genet. 2020. PMID: 31745289 Free PMC article.
Despite advances in the field of pharmacogenetics (PGx), clinical acceptance has remained limited. The Dutch Pharmacogenetics Working Group (DPWG) aims to facilitate PGx implementation by developing evidence-based pharmacogenetics guidelines to optimize pharm …
Despite advances in the field of pharmacogenetics (PGx), clinical acceptance has remained limited. The Dutch Pharmacogenetics …
Prospective DPYD genotyping to reduce the risk of fluoropyrimidine-induced severe toxicity: Ready for prime time.
Lunenburg CATC, Henricks LM, Guchelaar HJ, Swen JJ, Deenen MJ, Schellens JHM, Gelderblom H. Lunenburg CATC, et al. Eur J Cancer. 2016 Feb;54:40-48. doi: 10.1016/j.ejca.2015.11.008. Epub 2015 Dec 21. Eur J Cancer. 2016. PMID: 26716401 Review.
5-Fluorouracil (5-FU) and capecitabine (CAP) are among the most frequently prescribed anticancer drugs. They are inactivated in the liver by the enzyme dihydropyrimidine dehydrogenase (DPD). Up to 5% of the population is DPD deficient and these patients have a significantl …
5-Fluorouracil (5-FU) and capecitabine (CAP) are among the most frequently prescribed anticancer drugs. They are inactivated in the l …
Improving safety of fluoropyrimidine chemotherapy by individualizing treatment based on dihydropyrimidine dehydrogenase activity - Ready for clinical practice?
Meulendijks D, Cats A, Beijnen JH, Schellens JH. Meulendijks D, et al. Cancer Treat Rev. 2016 Nov;50:23-34. doi: 10.1016/j.ctrv.2016.08.002. Epub 2016 Aug 13. Cancer Treat Rev. 2016. PMID: 27589829 Review.
There is a consistent relationship between DPD activity and 5-FU exposure on the one hand, and risk of severe and potentially lethal fluoropyrimidine-associated toxicity on the other hand. Therefore, there is a sound rationale for individualizing treatment with fluoropyrim …
There is a consistent relationship between DPD activity and 5-FU exposure on the one hand, and risk of severe and potentially lethal …
Discovery of novel mutations in the dihydropyrimidine dehydrogenase gene associated with toxicity of fluoropyrimidines and viewpoint on preemptive pharmacogenetic screening in patients.
Del Re M, Michelucci A, Di Leo A, Cantore M, Bordonaro R, Simi P, Danesi R. Del Re M, et al. EPMA J. 2015 Sep 2;6(1):17. doi: 10.1186/s13167-015-0039-x. eCollection 2015. EPMA J. 2015. PMID: 26330892 Free PMC article.
MATERIALS AND METHODS: We selected three patients with colorectal adenocarcinoma who displayed unexpected severe adverse reactions after treatment with 5-FU and capecitabine. To investigate the possible involvement of deficient variants of the DPD gene …
MATERIALS AND METHODS: We selected three patients with colorectal adenocarcinoma who displayed unexpected severe adverse re …